This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Date:

November 13, 2024

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.

Source link

Phillip Lim Steps Down as Creative Director of 3.1 Phillip Lim

Nelly Furtado Says She Endured ‘Abusive Qualities' in Past Relationship

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Recent posts

Abercrombie & Fitch to see earnings ‘upside,’ but there’s potential margin pressure ahead: analyst

Investors are bracing for higher-for-even-longer interest rates

Oil prices lifted by report Iran may be planning another major strike on Israel

Nvidia CEO’s swagger isn’t enough to support the stock, as tiny cracks emerge

Here’s how stocks have performed under Biden and Harris vs. under Trump

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Worries about deficit spending after election bog down U.S. government debt

Skechers shares rise on $1 billion buyback, more upbeat outlook

Domino’s Pizza tops profit expectations but misses sales view

Amazon Prime Video’s ad event beat targets. That’s good news for the stock, says BofA.

Eli Lilly’s Alzheimer’s drug wins FDA approval

Republicans say that limiting immigration will help reduce inflation. Economists aren’t so sure.

This company’s performance is challenging the traditional definition of meme stocks

Will Trump nix Biden’s coverage plan for weight-loss drugs? It’ll be a close call.

Merck’s stock drops as mixed outlook offsets earnings beat on Keytruda strength

Related articles

Cocoa’s the best-performing commodity in 2024 — and even beat bitcoin. What’s next.

As the wealthy keep spending, here’s why the middle class is in for a tough 2025

How this Treasury-market dynamic could lead to the next big leg lower in stocks

As Teamsters go on strike, Amazon and its investors are trying to shrug it off

Oil may ‘collapse’ below $50 a barrel in 2025 if this perfect storm hits the market

New investigation rips Amazon’s safety record. That’s not slowing the tech giant’s stock.

U.S. oil prices drop nearly 1% on weak Chinese retail-sales data

UnitedHealth Group CEO says healthcare needs fixing. Start with these 3 problems in claims and patient costs, experts say.

Company

Follow us